Sex/Age (yrs) Year of SSc Onset/disease duration at skin biopsy (years) MRSS/score at skin biopsy Autoantibodies Lung involvment HRCT/PFT Heart involvement /Scleroderma renal crisis Raynaud’s phenomenon/ Digital ulcers F/46 2010/2 12/2 ANA/Scl-70 Normal/Normal Normal/No Yes/No F/21 2009/3 13/1 ANA/Scl-70 Normal/Normal Normal/No Yes/Yes F/31 2011/1 13/2 ANA/Scl-70 Normal/Normal Normal/No Yes/Yes F/36 2010/2 11/2 ANA/Scl-70 Normal/Normal  PAH/No Yes/Yes M/20 2010/2 11/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No F/41 2010/2 15/2 ANA/Scl-70 Normal/Normal Normal/No No/No F/30 2010/2 10/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No F/21 2010/2 09/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No F/31 2009/3 14/1 ANA/Scl-70 Normal/Normal Normal/No Yes/No F/42 2009/3 16/2 ANA/Scl-70 Fibrosis/Normal Normal/No Yes/No

MRSS: Modified Rodnan Skin Thickness Score (maximum possible score 51); HRCT: High Resolution Computed Tomography; PFT: Pulmonary Function Test; ANA: Antinuclear Antibodies; ACA: Anti-Centromere Antibodies; Scl-70 anti topoisomerase; PAH: Pulmonary Arterial Hypertension.

Table 1: Clinical and demographic features of the 10 diffuse SSc patients.